Posts tagged lsd
E35 The Future of Privacy

60% of Americans believe it’s impossible to go through their daily life without companies and the government collecting their data. And they’re right. But according to our guest Dr. Carissa Véliz, that’s not how it should be.

In this interview, Don MacPherson is joined by Dr. Carissa Véliz, an expert in digital ethics with an emphasis on privacy and AI ethics. They discuss the state of privacy today, the countless ways in which organizations track, store, and analyze our data, and the importance of maintaining our privacy both online and in the real world. Carissa offers advice for how to protect yourself online, and insights on how you can stand up and demand better data protection from organizations and the government.

Season Three of the podcast is dedicated to exploring the future and how life is sure to change over the next decade. This episode provides insight into how invasions of privacy and the fight to maintain it will disrupt the way we live and work.

Dr. Carissa Véliz, an Associate Professor at the Faculty of Philosophy and the Institute for Ethics in AI at the University of Oxford, is an expert in digital ethics. Dr. Véliz specializes in privacy and AI ethics along with political philosophy and public policy. Dr. Véliz is the author of Privacy is Power and the editor of the Oxford Handbook of Digital Ethics.

Read More
E34 The Future of Psychedelics

In this interview, Don MacPherson is joined by Dr. Matthew Johnson, an expert in psychoactive drug effects, addiction, and risk behavior. They discuss clinical research on psychedelics including psilocybin, ayahuasca, DMT, MDMA, LSD, and more. They dive into potential therapeutic applications for psychedelics including treating depression, PTSD, and addiction. They also explore the potential for psychedelics to improve individual happiness, creativity, empathy, and selflessness.

Season Three of the podcast is dedicated to exploring the future and how life is sure to change over the next decade. This episode provides insight into how research on clinical uses of psychedelics will disrupt the way we live and work.

Matthew W. Johnson, Ph.D., Professor at Johns Hopkins, is an expert in psychoactive drug effects, addiction, and risk behavior. He has worked with psychedelics since 2004. Dr. Johnson published psychedelic safety guidelines in 2008, which helped to resurrect psychedelic research. He developed and published the first psychedelic treatment of tobacco addiction in 2014. With colleagues, he conducted and published the largest study of psilocybin in cancer distress in 2016. His 2018 psilocybin review recommended psilocybin be moved to Schedule IV upon medical approval. He is Principal Investigator on upcoming psilocybin studies treating opioid addiction and PTSD, and LSD research treating chronic pain.

Read More